The causes of death varied by treatment type: colitis was frequently associated with anti-CTLA-4 related fatalities, while pneumonitis, hepatitis, and neurotoxic effects were more common in anti-PD-1/PD-L1 related deaths. Here, CTLA4 is linked to hepatitis A virus infection.